Movement Alert｜Duality Biotherapeutics-B Rises 6.27% in Regular Trading, Soochow Securities Initiates with Buy Rating and HK$418.61 Target

Market Focus07-10

On July 10, Duality Biotherapeutics-B (09606.HK) rose 6.27% in regular trading, trading at HK$215.2/share, with turnover of HK$35.54 million.

The rally was driven by continued market reaction to Soochow Securities initiating coverage on the company with a Buy rating and a target price of HK$418.61, implying approximately 90% upside from the current share price. Soochow Securities highlighted that Duality Bio is a global leader in the ADC (antibody-drug conjugate) space, forecasting revenue of RMB 2.052/2.395/2.599 billion for 2026-2028, representing year-on-year growth of 10.8%/16.7%/8.5%. The firm derived its target valuation of RMB 31.861 billion using DCF methodology.

The bullish thesis centers on two late-stage pipelines: DB-1311 (B7-H3 ADC) demonstrating differentiated efficacy in mCRPC with ORR of 42.3% and mOS of 22.5 months, and DB-1303 (HER2 ADC) approaching commercialization with its Chinese BLA accepted by NMPA. The company also exercised its US co-development and co-commercialization option for DB-1311 in May, and its Science and Technology Innovation Board IPO review has progressed to inquiry status.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198039714?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 09:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198039714","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Duality Biotherapeutics-B Rises 6.27% in Regular Trading, Soochow Securities Initiates with Buy Rating and HK$418.61 Target","media":"Market Focus","content":"<p><p>On July 10, Duality Biotherapeutics-B (09606.HK) rose 6.27% in regular trading, trading at HK$215.2/share, with turnover of HK$35.54 million.</p><p>The rally was driven by continued market reaction to Soochow Securities initiating coverage on the company with a Buy rating and a target price of HK$418.61, implying approximately 90% upside from the current share price. Soochow Securities highlighted that Duality Bio is a global leader in the ADC (antibody-drug conjugate) space, forecasting revenue of RMB 2.052/2.395/2.599 billion for 2026-2028, representing year-on-year growth of 10.8%/16.7%/8.5%. The firm derived its target valuation of RMB 31.861 billion using DCF methodology.</p><p>The bullish thesis centers on two late-stage pipelines: DB-1311 (B7-H3 ADC) demonstrating differentiated efficacy in mCRPC with ORR of 42.3% and mOS of 22.5 months, and DB-1303 (HER2 ADC) approaching commercialization with its Chinese BLA accepted by NMPA. The company also exercised its US co-development and co-commercialization option for DB-1311 in May, and its Science and Technology Innovation Board IPO review has progressed to inquiry status.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Duality Biotherapeutics-B Rises 6.27% in Regular Trading, Soochow Securities Initiates with Buy Rating and HK$418.61 Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Duality Biotherapeutics-B Rises 6.27% in Regular Trading, Soochow Securities Initiates with Buy Rating and HK$418.61 Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-10 09:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 10, Duality Biotherapeutics-B (09606.HK) rose 6.27% in regular trading, trading at HK$215.2/share, with turnover of HK$35.54 million.</p><p>The rally was driven by continued market reaction to Soochow Securities initiating coverage on the company with a Buy rating and a target price of HK$418.61, implying approximately 90% upside from the current share price. Soochow Securities highlighted that Duality Bio is a global leader in the ADC (antibody-drug conjugate) space, forecasting revenue of RMB 2.052/2.395/2.599 billion for 2026-2028, representing year-on-year growth of 10.8%/16.7%/8.5%. The firm derived its target valuation of RMB 31.861 billion using DCF methodology.</p><p>The bullish thesis centers on two late-stage pipelines: DB-1311 (B7-H3 ADC) demonstrating differentiated efficacy in mCRPC with ORR of 42.3% and mOS of 22.5 months, and DB-1303 (HER2 ADC) approaching commercialization with its Chinese BLA accepted by NMPA. The company also exercised its US co-development and co-commercialization option for DB-1311 in May, and its Science and Technology Innovation Board IPO review has progressed to inquiry status.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1198039714","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198039714","pubTimestamp":1783648124,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 10, Duality Biotherapeutics-B (09606.HK) rose 6.27% in regular trading, trading at HK$215.2/share, with turnover of HK$35.54 million.The rally was driven by continued market reaction to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"走势提示|双力生物-B常规交易涨6.27%，东吴证券给予买入评级，目标价418.61港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On July 10, Duality Biotherapeutics-B (09606.HK) rose 6.27% in regular trading, trading at HK$215.2/share, with turnover of HK$35.54 million.The rally was driven by continued market reaction to Soochow Securities initiating coverage on the company with a Buy rating and a target price of HK$418.61, implying approximately 90% upside from the current share price. Soochow Securities highlighted that Duality Bio is a global leader in the ADC (antibody-drug conjugate) space, forecasting revenue of RMB 2.052/2.395/2.599 billion for 2026-2028, representing year-on-year growth of 10.8%/16.7%/8.5%. The firm derived its target valuation of RMB 31.861 billion using DCF methodology.The bullish thesis centers on two late-stage pipelines: DB-1311 (B7-H3 ADC) demonstrating differentiated efficacy in mCRPC with ORR of 42.3% and mOS of 22.5 months, and DB-1303 (HER2 ADC) approaching commercialization with its Chinese BLA accepted by NMPA. The company also exercised its US co-development and co-commercialization option for DB-1311 in May, and its Science and Technology Innovation Board IPO review has progressed to inquiry status.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198039714","isCrawlerRequest":true}